Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders (Abomination Shot Adverse Events)

Todd Calendar and Jeffrey Prather Plandemic Discussionhttps://rumble.com/v22j240-todd-calendar-and-jeffrey-prather-the-great-reset.html

Stew Peters the Plandemic Continues (Flu, RSV, Covid)https://rumble.com/v22gtzk-live-globalists-plot-next-catastrophic-plandemic-obgyn-dr.-thorp-exposes-fe.html

https://finance.yahoo.com/news/acer-therapeutics-relief-therapeutics-announce-133000350.html#amp_tf=From%20%251%24s&aoh=16721753447033&csi=0&referrer=https%3A%2F%2Fwww.google.com&ampshare=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Facer-therapeutics-relief-therapeutics-announce-133000350.html

New FDA-approved formulation for patients living with urea cycle disorders

NEWTON, Mass. and GENEVA, Dec. 27, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), today announced that the U.S. Food and Drug Administration (FDA) has approved OLPRUVA™ (sodium phenylbutyrate) for oral suspension in the U.S. for the treatment of certain patients living with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).

“The FDA’s approval of OLPRUVA™, an innovative formulation of sodium phenylbutyrate packaged for the first time in single-dose envelopes, marks the culmination of our ongoing dedication to develop new and differentiated treatment options for those affected by rare diseases,” said Chris Schelling, chief executive officer and founder of Acer. “Patients who are living with UCDs now have an alternative treatment option with OLPRUVA™, to address some of the challenges they may have with existing therapy. We are pleased to be able to provide a new, approved treatment choice for those living with this challenging disease.”

Mr. Schelling continued, “This approval represents the first FDA-approved product for Acer, validating our ability to identify and develop treatments where science can be applied in novel ways and make them available to patients as quickly and efficiently as possible. In addition, this approval unlocks our Marathon debt funding option and provides us with resources to advance our pipeline of investigational product candidates.”



The Depopulation Agenda Plan is commencing..

Please repent, carry your cross daily and accept the free gift of Jesus Christ’s Death on the Cross for payment for your sins.

#Yahweh #Yeshua #HolySpirit #LordAlmighty #SovereignLord #Nameaboveallnames #TheWay #TheTruth #TheLife #TheGate #Heaven #KingdomofHeaven  #Saved #Glorified #Endtimes #LastDays #FeastofTrumpets #markofthebeast #verseoftheday #birthpains #Judgement #Christian #Christianity #hope #love #Jesus  #Christ 

Leave a Reply

Powered by WordPress.com.

Up ↑

%d bloggers like this: